Chimeric Therapeutics announces breakthrough AML response with CHM CORE-NK in Phase 1B trial
Chimeric Therapeutics has reported a significant milestone in its ongoing clinical trials, wherein a patient diagnosed with Acute Myelogenous Leukemia (AML) has exhibited a complete ... Read More
Penn in disarray: President Magill’s resignation sparks heated debate and investigation
In a dramatic turn of events, University of Pennsylvania President Elizabeth Magill has announced her resignation, following intense backlash over her response during a congressional ... Read More
Gilead’s Kite to acquire CAR T-therapies developer Tmunity Therapeutics
Kite, an arm of Gilead Sciences, has agreed to acquire Tmunity Therapeutics, a Philadelphia-based clinical-stage biotech company focused on next-generation CAR T-therapies and technologies, for ... Read More